Navigation Links
First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
Date:2/11/2009

ts are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements, including whether experimental pain models of pain, including the capsaicin model, are accurate in predicting efficacy of novel analgesics in early clinical trials, whether the results of any Phase II trial or other study of NGX426 will be consistent with the results of the study reported in this press release, whether TorreyPines will be able to complete any potential strategic or financing transaction on terms acceptable to TorreyPines' stockholders, how the volatile economic environment will affect TorreyPines' efforts to complete a strategic or financing transaction, whether TorreyPines' cash resources will be sufficient to fund operations as planned, whether any preclinical studies or clinical trials, either ongoing or conducted in the future, will prove successful, and if successful, whether the results can be replicated; whether safety and efficacy profiles of any of the company's product candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; whether pre-clinical results will be substantiated by ongoing or future clinical trials, if any, or whether any of the company's product candidates will be able to improve the signs or symptoms of their respective clinical indication; whether any of the company's product candidates will support a filing for marketing approval, will be approved by the regulatory authorities, or if approved, will prove competitive in the market; or whether the necessary financing to support the company's product development programs will be available. In particular there is no guarantee that clinical trials of any of the company's product candidates will be completed on schedule or that results of these clinical tri
'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Max Muscle Introduces First-Ever Probiotics Protein Bar
2. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
3. Hoya Announces Third Quarter and the First Nine Months Financial Results for FY2008
4. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
6. World's First Website for Patients to Share Diagnostic-Quality Medical Images
7. Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the Worlds First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop
8. BioComp Pharma Launches First Generic Drug for Tindamax(R)
9. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
10. Complete Genomics to Release Its DNA Sequencing Data for the First Time at Advances in Genome Biology and Technology Annual Meeting
11. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014 EnGeneIC, Ltd. , ... treatment of cancer through the targeted delivery of ... together with the Asbestos Disease Research Institute (ADRI), ... South Wales (NSW) Premier,s Award for Excellence in ... the hospitals that will be involved in the ...
(Date:9/15/2014)... researchers led by Northeastern University has developed a ... and a variety of nanocarbon structures in carbon ... scalable, which will allow the researchers to tailor ... in applications ranging from electronic devices to CNT-reinforced ... sports equipment. , Their findings were published in ...
(Date:9/15/2014)... , Sept. 15, 2014 The chemistry, taste, ... climate, says a new article published by the nonprofit American ... PhD, on climate change and its effects on the phytochemical ... an extensive study conducted by Dr. Ahmed in the ... and has implications for the future of medicinal ...
(Date:9/15/2014)... 2014  The second annual International Plasma Awareness ... joint initiative of the Plasma Protein Therapeutics Association ... is designed to: , Raise global awareness ... of plasma donors in saving and improving lives ... rare diseases Member companies are planning ...
Breaking Biology Technology:EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3
... June 1, 2011 VWR International, LLC, a ... announced today that it acquired the business of ... Founded in 1985, BioExpress is a well-respected ... segments, and offers over 200 well-known, multi-national brands, ...
... ( www.investoruprising.com ) has released "A Guide to Biotech ... Exchange Traded Funds (ETFs) and mutual funds, which is ... (Logo: http://photos.prnewswire.com/prnh/20110411/NY80781LOGO-a) "A Guide to ... the leading biotech mutual funds and ETFs. It explains ...
... Waters Corporation (NYSE: WAT ) ... System, the highest performing UPLC® system ever engineered ... level.  For scientists challenged by the most difficult ... system dispersion and lowest carryover in the industry ...
Cached Biology Technology:VWR International, LLC Acquires BioExpress Corp. 2Investor Uprising Publishes Free Biotech Investment Report 2Investor Uprising Publishes Free Biotech Investment Report 3Waters Introduces Highest Performing UPLC Ever Engineered - the New ACQUITY UPLC I-Class 2Waters Introduces Highest Performing UPLC Ever Engineered - the New ACQUITY UPLC I-Class 3Waters Introduces Highest Performing UPLC Ever Engineered - the New ACQUITY UPLC I-Class 4
(Date:9/15/2014)... fears that reef biodiversity may not provide the level ... , In an international study published today, Professor David ... Reef Studies (Coral CoE) says we need to identify ... , In coral reefs, just as in any modern-day ... safe and functioning. , Professor Bellwood says, in ...
(Date:9/15/2014)... vision document, released today by the National Academy ... goals, objectives, and strategies for the program and ... next five years (2015-2020). In addition, the ... be funded in 2015, will include exploratory grants, ... , The $500 million, 30-year program to be ...
(Date:9/15/2014)... Conditions on Earth for the first 500 million years ... the present day, complete with oceans, continents and active ... geologic eon, called the Hadean, has gained substantial new ... that formed more than 4 billion years ago with ... as a possible geological analog for early Earth. , ...
Breaking Biology News(10 mins):Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4Early Earth less hellish than previously thought 2Early Earth less hellish than previously thought 3
... and Matthew Champion from the University of Notre Dame,s ... to directly detect bacterial protein secretion, which could provide ... The Champions point out that bacteria ... beyond their cell membrane in order to interact with ...
... by several orders of magnitude. The molecular mechanism by which ... and thus slows cell growth is described by biophysicists at ... the Online Early Edition of the journal PNAS . ... showed that Ras puts a phosphate chain under tension to ...
... MA A new article published today in ... evidence to suggest the current obesity epidemic in the ... high fructose corn syrup (HFCS). The commentary concludes ... research, there is overwhelming evidence showing HFCS is nutritionally ...
Cached Biology News:Notre Dame research could provide new insights into tuberculosis and other diseases 2RUB researchers clarify catalysis mechanism of cell growth protein Ras 2RUB researchers clarify catalysis mechanism of cell growth protein Ras 3Scientists conclude high fructose corn syrup should not be blamed for obesity 2
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... The MitoPT kit is used in conjunction with ... culture and induce apoptosis according to your existing ... as a negative control). Once you have induced ... solution to each population and incubate the cells ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: